Insider · CIK 0001741968
Chris Degnan
Files at URGN (UroGen Pharma Ltd.). First filing Oct 9, 2025, latest Oct 9, 2026.
In brief
Chris Degnan files SEC Form 4 as CFO at URGN (UroGen Pharma Ltd.). Since Oct 9, 2025, Chris Degnan has reported 0 open-market buys worth $0 and 2 open-market sells worth $118k, the latest filed on Oct 9, 2026.
A track record needs three past buys with six months of prices behind them; Chris Degnan has 0, so none is measured yet.
The newest scored trade: sold $81k of URGN on Oct 8, 2026, filed Oct 9, 2026, scored 26 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $81k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
URGN: UroGen Pharma Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | URGNsell UroGen Pharma Ltd. | $81k 2,202 shares | -33% | +125% from low-26% from high | |
| 23Weak | URGNsell UroGen Pharma Ltd. | $37k 2,203 shares | -49% | +341% from low-19% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 9, 2026 | URGN UroGen Pharma Ltd. | 2,202 0.00% of outstanding | $90k | Oct 8, 2026 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +4,483 | - | - | 6,763 | 5 d ago |
| Oct 8, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -2,202 | $36.69 | $81k | 4,561 | 5 d ago |
| Oct 8, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -4,483 | $0.00 | $0 | 4,484 | 5 d ago |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | AGrant or award Restricted Stock Unitsderivative | +32,609 | $0.00 | $0 | 32,609 | Feb 3, 2026 |
| Oct 8, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +4,483 | - | - | 4,483 | Oct 9, 2025 |
| Oct 8, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -2,203 | $16.85 | $37k | 2,280 | Oct 9, 2025 |
| Oct 8, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -4,483 | $0.00 | $0 | 8,967 | Oct 9, 2025 |
Questions about Chris Degnan
Answered from the filings on this page, as of the latest one.
Is Chris Degnan buying or selling?
In the last 12 months Chris Degnan reported 0 open-market buys worth $0 and 1 open-market sell worth $81k on SEC Form 4; the latest was sold $81k of URGN on Oct 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Chris Degnan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Chris Degnan has 0.
Where does Chris Degnan file Form 4?
Chris Degnan has filed Form 4 at URGN (UroGen Pharma Ltd.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.